Medical therapy of Graves' disease: Does thyroxine prevent recurrence of hyperthyroidism?

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 8, 1997, Pages 2410-2413

  Lucas, A ^a   Salinas, I ^a   Rius, F ^a   Pizarro, E ^a   Granada, M L ^a   Foz, M ^a   Sanmarti A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; HORMONE BINDING PROTEIN; LEVOTHYROXINE; LIOTHYRONINE; MICROSOME ANTIBODY; THYROGLOBULIN ANTIBODY; THYROTROPIN; THYROXINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTITHYROID AGENTS; AUTOANTIBODIES; CARBIMAZOLE; CHILD; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, THYROTROPIN; RECURRENCE; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0030838439     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.8.2410     Document Type: Article

References (31)

1. Solomon B, Glinoer D, Lagasse R, Wartofsky L. 1990 Current trends in the management of Graves' disease. J Clin Endocrinol Metab. 70:1518-1524.
2. Klein I, Becker DV, Levey GS. 1994 Treatment of hyperthyroid disease. Ann Intern Med. 121:281-288.
3. Franklyn JA. 1994 The management of hyperthyroidism. N Engl J Med. 330:1731-1738.
4. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. 1996 Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 334:220-224.
5. Young ET, Steel NR, Tailor JJ, et al. 1988 Prediction of remission after antithyroid drug treatment in Graves' disease. Q J Med. 66:175-189.
6. Allannic H, Fauchet R, Orgiazzi J, et al. 1990 Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 70:675-679.
7. Romaldini JH, Bromberg N, Werner RS, et al. 1983 Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab. 57:563-570.
8. Hashizume K, Ichikawa K, Sakurai A, et al. 1991 Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med. 324:947-953.
9. Tamai H, Nakagawa T, Fukino O, et al. 1980 Thionamide therapy in Graves' disease: relation of relapsed rate to duration of therapy. Ann Intern Med. 92:488-490.
10. Marcocci C, Chiovato L, Mariotti S, Pinchera A. 1982 Changes of circulating thyroid autoantibody levels during and after therapy with methimazole in patients with Graves' disease. J Endocrinol Invest. 5:13-19.
11. Weetman AP, McGregor AM, Hall R. 1984 Evidence for an effect of antithyroid drugs on the natural history of Graves' disease. Clin Endocrinol. 21:163-167.
12. Kou SW, Huang WS, Hu CA, Liao WK, Fung TC, Wu SY. 1994 Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy. Eur J Endocrinol. 131:125-130.
13. Volpé R. 1994 Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. Thyroid. 4:217-223.
14. Reinwein D, Benker G, Lazarus JH, et al. 1993 A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. J Clin Endocrinol Metab. 76:1516-1521.
15. Edmonds CJ, Tellez M. 1994 Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose. Eur J Endocrinol. 131:120-124.
16. Tamai H, Hayaki I, Keisuke K, et al. 1995 Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. J Clin Endocrinol Metab. 80:1481-1484.
17. Serra Majem L, Lloveras G, Vila L, Salleras L. 1993 Estrategias para la prevención y el control de los trastornos ocasionados por la deficiencia de yodo en Cataluña. Endocrinologia. 40:273-277.
18. Classification of eye changes of Graves disease. 1992 Thyroid. 2:235-236.
19. Glinoer D, Hesch D, Lagasse R, Laurberg P. 1987 The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinol (Copenh). 185 [Suppl]:9-37.
20. Weetman AP, McGregor AM. 1994 Autoimmune thyroid disease: Further developments in our understanding. Endocr Rev. 15:788-830.
21. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Rees Smith B, Hall R. 1980 Carbimazole and the autoimmune response in Graves' disease. N Engl J Med. 303:302-307.
22. Young RJ, Sherwoord MB, Simpson JG, Nicol AG, Michie W, Beck JS. 1976 Histometry of lymphoid infiltrate in the thyroid of primary thyrotoxicosis patients. J Clin Pathol. 29:398-402.
23. Romaldini JH, Werner MC, Rodrígues HF, et al. 1986 Graves' disease and Hashimoto's thyroiditis: effect of high doses of antithyroid drugs on thyroid autoantibody levels. J Endocrinol Invest. 9:233-238.
24. Paschke R, Vogg M, Kristoferitsch R, et al. 1995 Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease. J Clin Endocrinol Metab. 80:2470-2474.
25. Jansson R, Dahlberg A, Johansson H, Lindström B. 1983 Intrathyroidal concentrations of methimazole in patients with Graves' disease. J Clin Endocrinol Metab. 57:129-132.
26. Ballard PL, Hovey ML, Gonzales LK. 1984 Thyroid hormone stimulation of phosphatidiylcholine synthesis in cultured fetal rabbit lung. J Clin Invest. 74:898-905.
27. Goñi MJ, Forga L, Iriarte A, Anda E, Rodríguez R, Menéndez E. 1995 Recidivas en la enfermedad de Graves-Basedow: influencia de la pauta de tratamiento. Med Clin (Barc). 104:11-14.
28. Escobar-Morreale HF, Serrano-Gotarredona J, Villar LM, et al. 1996 Methimazole has no dose-related effect on the serum concentrations of soluble class 1 major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta2-microglobulin in patients with Graves' disease. Thyroid. 6:29-36.
29. Rizvi A, Crapo LM. 1996 Failure of thyroxine therapy for Graves disease. Ann Intern Med. 124:694.
30. Feldt-Rasmussen U, Schleusener H, Carayon P. 1994 Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab. 78:98-102.
31. Hershman JM. 1995 Editorial: Does thyroxine therapy prevent recurrence of Graves' hyperthyroidism? J Clin Endocrinol Metab. 80:1479-1480.